Cargando…
A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations
In recent years, the wealth of basic science research supporting resveratrol's potential to treat, delay, and even prevent age-related chronic diseases has led to a number of human clinical trials. While such translational research has yielded promising results in clinical populations, recently...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765578/ https://www.ncbi.nlm.nih.gov/pubmed/24073437 |
_version_ | 1782283342764310528 |
---|---|
author | Smoliga, James M. Colombo, E. Sage Campen, Matthew J. |
author_facet | Smoliga, James M. Colombo, E. Sage Campen, Matthew J. |
author_sort | Smoliga, James M. |
collection | PubMed |
description | In recent years, the wealth of basic science research supporting resveratrol's potential to treat, delay, and even prevent age-related chronic diseases has led to a number of human clinical trials. While such translational research has yielded promising results in clinical populations, recently published conflicting results from studies evaluating resveratrol's potential for primary prevention of chronic disease in healthy / asymptomatic individuals have generated considerable controversy and do not initially appear consistent with findings from animal models. We argue that trials targeting healthy humans are often fundamentally flawed owing to inappropriate use of paradigms only applicable to populations with overt clinical disease and the consequent misleading (typically negative) results can severely retard advancement of drug development. To appropriately perform translational research centered on resveratrol as a primary prevention agent in non-clinical populations, it is critical to utilize study designs which can provide adequate information on clinically relevant outcome measures, avoid paradigms and assumptions from interventions which are specific to clinical populations, and maintain realistic expectations compared to interventions which provide the theoretical maximal response (e.g., caloric restriction and aerobic exercise training). |
format | Online Article Text |
id | pubmed-3765578 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-37655782013-09-10 A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations Smoliga, James M. Colombo, E. Sage Campen, Matthew J. Aging (Albany NY) Research Perspective In recent years, the wealth of basic science research supporting resveratrol's potential to treat, delay, and even prevent age-related chronic diseases has led to a number of human clinical trials. While such translational research has yielded promising results in clinical populations, recently published conflicting results from studies evaluating resveratrol's potential for primary prevention of chronic disease in healthy / asymptomatic individuals have generated considerable controversy and do not initially appear consistent with findings from animal models. We argue that trials targeting healthy humans are often fundamentally flawed owing to inappropriate use of paradigms only applicable to populations with overt clinical disease and the consequent misleading (typically negative) results can severely retard advancement of drug development. To appropriately perform translational research centered on resveratrol as a primary prevention agent in non-clinical populations, it is critical to utilize study designs which can provide adequate information on clinically relevant outcome measures, avoid paradigms and assumptions from interventions which are specific to clinical populations, and maintain realistic expectations compared to interventions which provide the theoretical maximal response (e.g., caloric restriction and aerobic exercise training). Impact Journals LLC 2013-07-20 /pmc/articles/PMC3765578/ /pubmed/24073437 Text en Copyright: © 2013 Smoliga et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited |
spellingShingle | Research Perspective Smoliga, James M. Colombo, E. Sage Campen, Matthew J. A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations |
title | A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations |
title_full | A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations |
title_fullStr | A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations |
title_full_unstemmed | A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations |
title_short | A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations |
title_sort | healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations |
topic | Research Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765578/ https://www.ncbi.nlm.nih.gov/pubmed/24073437 |
work_keys_str_mv | AT smoligajamesm ahealthierapproachtoclinicaltrialsevaluatingresveratrolforprimarypreventionofagerelateddiseasesinhealthypopulations AT colomboesage ahealthierapproachtoclinicaltrialsevaluatingresveratrolforprimarypreventionofagerelateddiseasesinhealthypopulations AT campenmatthewj ahealthierapproachtoclinicaltrialsevaluatingresveratrolforprimarypreventionofagerelateddiseasesinhealthypopulations AT smoligajamesm healthierapproachtoclinicaltrialsevaluatingresveratrolforprimarypreventionofagerelateddiseasesinhealthypopulations AT colomboesage healthierapproachtoclinicaltrialsevaluatingresveratrolforprimarypreventionofagerelateddiseasesinhealthypopulations AT campenmatthewj healthierapproachtoclinicaltrialsevaluatingresveratrolforprimarypreventionofagerelateddiseasesinhealthypopulations |